Transgenomic Announces Q1 2015 Launch of Its Multiplexed ICE COLD-PCR™ Technology That Enables Wide Use of Liquid Biopsies and Personalized Medicine
Multiplexed ICE COLD-PCRTM delivers major advantages compared to current sequencing technologies used on their own. It delivers at least a 100-fold improvement in sensitivity, detecting previously unknown genetic alterations along with those that are already known. Its ultra-high sensitivity makes it feasible to conduct comprehensive genomic analyses using either tissue or liquid biopsies, by accurately analyzing cell-free tumor DNA circulating in the blood or other bodily fluids. Importantly, MX ICP is platform agnostic—it works on all the sequencing platforms found in labs today, greatly enhancing the sensitivity of next generation sequencing, Digital PCR, Sanger, and other platforms. MX-ICP is easy to use, is highly reliable and is easily implemented, requiring minimal disruption to current sequencing processes or procedures.